Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Spermatogenesis-associated protein 24 (SPATA24)
- Target
- SPATA24
- Molecular classification
- Other (protein coding gene, not classified as receptor, channel, enzyme, etc.), Coiled-coil domain containing family, DNA-binding protein
01
Overview
SPATA24 (Spermatogenesis-associated protein 24) is a DNA-binding protein that is predicted to participate in regulation of gene expression with synergistic effects on certain promoter activation, notably working with GMNN and TBP family proteins. Its main recognized roles are in cell differentiation and spermatogenesis, where it may be especially relevant to cytoplasm movement and removal during spermiogenesis[1][7][5][6]. The protein is found in both the cytosol and nucleoplasm. While aberrant expression and somatic mutation of SPATA24 have been observed in malignant tissues (colorectal, endometrial, breast, cervical cancers), its direct disease role is not well characterized and it is not currently considered a therapeutic target[2][4][9].
- Other names
- CCDC161T6441Testis protein T6441 homologCoiled-coil domain containing 161TIPTTIPT22700012K08Rik (mouse)Spermatogenesis associated 24
02
Mechanism of action
Not applicable; there are currently no drugs that act via modulation or inhibition/activation of this protein
03
Biological functions
DNA bindingProtein homodimerizationRegulation of TATA box-containing promoters (synergistic activation with GMNN and TBP)Activation of NF1 TATA-less promotersInvolvement in cell differentiationInvolvement in spermatogenesis (may play a role during spermiogenesis)
04
Disease associations
Other: Expression is altered in several cancers (colorectal, breast, cervical, endometrial) and may be involved in malignant transformationNot a well-established cancer driver; found in mutation analyses for various carcinomas
05
Safety considerations
None reported. There are no known safety concerns or adverse events associated with this molecule as a drug target
06
Interacting drugs
No known drugs directly interact with SPATA24 as a target
07
Biomarkers
Not established as a clinical biomarker for disease or patient selection
Beyond the preview
Go deeper on Spermatogenesis-associated protein 24 (SPATA24).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Spermatogenesis-associated protein 24 (SPATA24).